Author name: Neurad Diagnostic

Recurrent episodes of low blood sugar (hypoglycemia), particularly after fasting or exercise, can be debilitating and dangerous. When all conventional causes have been excluded, one important diagnosis to consider is an insulinoma — a rare tumor of the pancreatic beta cells. Finding these tiny tumors has historically been one of the most challenging tasks in medicine. The Exendin PET Scan, available at Neurad Diagnostics in Delhi, is now considered the most accurate imaging tool for insulinoma localization, with accuracy rates that far exceed all conventional imaging methods. This guide explains everything you need to know about the 68Ga-Exendin PET/CT scan. Leading research centers including those affiliated with the Endocrine Society have validated 68Ga-Exendin PET as the most accurate imaging modality for insulinoma localization, with studies in the Journal of the Endocrine Society confirming sensitivity rates exceeding 95%. this imaging test at Neurad Diagnostics Delhi — Precise insulinoma localization Table of Contents What Is an Exendin PET Scan? Why Doctors Recommend the the procedure Diseases and Conditions Diagnosed by the Exendin scan Who Needs an Exendin PET Scan? Symptoms That May Lead to the procedure How the Exendin PET Scan Procedure Works Preparation Before the this imaging test Step-by-Step the Exendin scan Procedure at Neurad Diagnostics Advantages of this PET/CT Technology Accuracy and Clinical Benefits Safety Information Cost of Exendin PET Scan in Delhi NCR Why Choose Neurad Diagnostics for the Exendin scan in Delhi? Frequently Asked Questions About this PET/CT 1. What is an insulinoma? 2. Why is the procedure the best test for insulinoma? 3. Can Exendin PET find insulinomas that CT and MRI missed? 4. Is special preparation required for Exendin PET Scan? 5. Can Exendin PET detect malignant insulinomas? 6. Where can I get this scan in India? 7. How long does the Exendin PET Scan take? 8. Is the Exendin scan useful for children with congenital hyperinsulinism? 9. Does the Exendin PET Scan hurt? 10. What happens after an insulinoma is found on Exendin PET? Conclusion — Book Your this scan at Neurad Diagnostics Delhi What Is an Exendin PET Scan? The the Exendin scan, formally known as 68Ga-Exendin-4 PET/CT (or 68Ga-NOTA-Exendin-4 PET/CT), is a highly specialized nuclear medicine imaging procedure that uses a Gallium-68 labelled form of Exendin-4 — a GLP-1 (Glucagon-Like Peptide-1) receptor agonist peptide — to detect and localize tumors expressing GLP-1 receptors (GLP-1R). These receptors are massively overexpressed (up to 460-fold) on insulinoma cells compared to normal pancreatic tissue, giving the this PET/CT extraordinary sensitivity for this notoriously difficult-to-find tumor. Insulinomas are the most common functional pancreatic neuroendocrine tumor, but they are typically very small (90% are less than 2 cm) and solitary. Their small size makes them invisible or very hard to find on CT, MRI, or even intraoperative ultrasound in a significant proportion of cases. The Exendin PET Scan solves this problem by imaging GLP-1 receptor expression directly — lighting up insulinoma cells with exceptional contrast against the surrounding pancreatic tissue. At Neurad Diagnostics in Delhi, we offer this highly specialized imaging study, which is available at only a handful of centers across India. Why Doctors Recommend the the procedure Endocrinologists, gastroenterologists, and endocrine surgeons recommend this scan primarily for the preoperative localization of insulinomas in patients with confirmed endogenous hyperinsulinemic hypoglycemia. The clinical challenge is enormous: without precise preoperative localization, surgeons may need to perform extensive pancreatic exploration or even distal pancreatectomy based on intraoperative findings — increasing surgical risk and morbidity substantially. When the Exendin PET Scan localizes the tumor preoperatively, surgeons can plan a minimally invasive, targeted enucleation of the tumor, preserving maximum pancreatic tissue and dramatically reducing surgical risk. Beyond insulinoma localization, the this imaging test also has emerging applications in GLP-1R-expressing NETs and in post-bariatric hypoglycemia (where diffuse beta cell hyperplasia may be distinguished from focal insulinoma). It is also being investigated for beta cell mass measurement in diabetes research contexts. Diseases and Conditions Diagnosed by the Exendin scan Insulinoma: Primary indication — the most accurate imaging tool available for insulinoma localization Ectopic Insulinoma: Detects insulinomas in unusual locations (duodenal wall, mesentery) missed by all other imaging Persistent Hyperinsulinemic Hypoglycemia of Infancy (PHHI)/Congenital Hyperinsulinism: Differentiates focal from diffuse disease in children Post-bariatric Hypoglycemia: Helps distinguish focal nesidioblastosis from diffuse beta cell hyperplasia Other GLP-1R-expressing NETs: Some non-functioning pancreatic NETs and GEP-NETs express GLP-1R Gastrinoma: Can show GLP-1R expression Who Needs an Exendin PET Scan? Your endocrinologist or surgeon may refer you for an this PET/CT in Delhi if: You have biochemically confirmed endogenous hyperinsulinemic hypoglycemia (Whipple’s triad positive) CT and/or MRI have failed to localize an insulinoma You are being evaluated for pancreatic surgery for hypoglycemia You have recurrent hypoglycemia after bariatric surgery You have a child with congenital hyperinsulinism requiring focal vs. diffuse disease differentiation Your oncologist suspects a GLP-1R-expressing pancreatic neuroendocrine tumor Prior imaging was inconclusive for small pancreatic tumor localization Symptoms That May Lead to the procedure The clinical presentation of insulinoma is characterized by Whipple’s Triad — the combination of hypoglycemic symptoms, documented low blood glucose, and relief of symptoms with glucose. Specific symptoms include: Episodic sweating, trembling, palpitations (autonomic symptoms of hypoglycemia) Confusion, cognitive impairment, or behavioral changes during episodes Seizures or loss of consciousness Headache and visual disturbances Hunger and weight gain (due to frequent carbohydrate intake to prevent hypoglycemia) Symptoms that occur during fasting or exercise and are relieved by eating Episodes documented in the hospital during supervised 72-hour fast test How the Exendin PET Scan Procedure Works The this scan works by exploiting the extraordinarily high expression of GLP-1 receptors on insulinoma cells. Exendin-4 is a peptide that binds with extremely high affinity and selectivity to GLP-1R. When labelled with Gallium-68 and injected intravenously, it circulates through the blood and binds to GLP-1R-expressing cells — primarily insulinoma cells and normal beta cells of the pancreas. However, insulinoma cells express GLP-1R at levels far exceeding normal beta cells, creating a clearly detectable focal hotspot on the PET image that corresponds to the tumor location. A critical procedural

Cancer diagnosis is entering a new era, and at the forefront of this transformation is the FAPI PET Scan. If your oncologist has recommended this advanced imaging study, or if you want to understand all your diagnostic options, this guide provides comprehensive information about the 68Ga-FAPI PET/CT scan available at Neurad Diagnostics in Delhi. The this scan is rapidly emerging as one of the most powerful tools in oncologic imaging, offering a completely new way to visualize cancer that complements — and in many cases surpasses — conventional FDG PET scanning. According to clinical research published in the Journal of Nuclear Medicine, 68Ga-FAPI PET demonstrates superior tumor-to-background contrast compared to FDG PET in multiple cancer types including gastric, pancreatic, and biliary cancers. The European Association of Nuclear Medicine (EANM) recognizes FAPI imaging as a promising advancement in oncologic molecular imaging. FAPI PET Scan at Neurad Diagnostics Delhi — Next-generation cancer imaging for multiple tumor types Table of Contents What Is a the FAPI scan? Why Doctors Recommend the this scan Cancers and Diseases Detected by this imaging test Who Needs a FAPI PET Scan? Symptoms That May Lead to the procedure How the FAPI PET Scan Procedure Works Preparation Before the this imaging test Step-by-Step the FAPI scan Procedure at Neurad Diagnostics Advantages of this PET/CT Technology Accuracy and Clinical Benefits Safety Information Cost of FAPI PET Scan in Delhi NCR Why Choose Neurad Diagnostics for FAPI PET Scan in Delhi? Frequently Asked Questions About this PET/CT 1. What does FAPI stand for? 2. Is FAPI PET better than FDG PET? 3. Do I need to fast for the procedure? 4. Can FAPI PET detect peritoneal metastases? 5. Is FAPI PET used for treatment planning? 6. Can normal tissues show FAPI uptake? 7. How is FAPI PET different from DOTANOC PET? 8. Where can I get this scan in Delhi? 9. Is FAPI PET Scan approved for routine use? 10. Can the FAPI scan detect cancer recurrence? Conclusion — Book Your FAPI PET Scan at Neurad Diagnostics Delhi What Is a the FAPI scan? The this PET/CT, formally known as 68Ga-FAPI PET/CT, is a cutting-edge nuclear medicine imaging study that uses a Gallium-68 labelled tracer called Fibroblast Activation Protein Inhibitor (FAPI). This tracer targets Fibroblast Activation Protein (FAP) — an enzyme that is massively overexpressed by cancer-associated fibroblasts (CAFs) in the tumor microenvironment of a wide variety of solid cancers. FAP is expressed at extremely low levels in normal healthy tissues, which gives the FAPI PET Scan exceptionally high tumor-to-background contrast — making tumors stand out brightly against a very clean background image. What makes FAPI unique is that it does not target the cancer cells directly but rather the reactive stromal cells that surround and support tumors. This is a completely different biological target from FDG (which measures glucose metabolism) or PSMA (which targets prostate cancer cells). As a result, the procedure can detect cancers that are FDG-negative, and can image tumors in locations with high background FDG activity (like the brain, liver, stomach, and inflamed tissues) with far superior clarity. Neurad Diagnostics is among the pioneering centers in Delhi NCR offering this next-generation diagnostic technology. Why Doctors Recommend the this scan Oncologists, radiation oncologists, and surgical oncologists recommend FAPI PET Scan in situations where conventional imaging fails or provides suboptimal information. Key clinical indications include: For cancers with low FDG avidity — such as mucinous tumors, well-differentiated carcinomas, or hepatocellular carcinoma — FAPI PET often detects disease that a standard FDG PET scan would miss entirely. For tumors in the liver, brain, or peritoneum where high normal tissue FDG uptake obscures lesions, FAPI’s very low background signal provides dramatically better visualization. For radiotherapy treatment planning, FAPI PET precisely delineates the extent of the tumor microenvironment, allowing more accurate target volume definition. And for patients being evaluated for FAP-targeted radionuclide therapy — an emerging treatment approach — FAPI PET confirms receptor expression and treatment eligibility. Cancers and Diseases Detected by this imaging test The the FAPI scan is effective across a remarkable range of solid tumors due to the near-universal overexpression of FAP in cancer-associated fibroblasts. High-performance cancers for FAPI imaging include: Gastric Cancer (Stomach Cancer): Among the highest FAP expression — FAPI PET shows exceptional performance Cholangiocarcinoma (Bile Duct Cancer): Very high FAP expression makes FAPI superior to FDG in many cases Pancreatic Ductal Adenocarcinoma: FAPI PET often outperforms FDG PET for this difficult-to-image cancer Lung Cancer: Both adenocarcinoma and squamous cell carcinoma show high FAPI uptake Breast Cancer: Particularly useful in lobular breast cancer where FDG uptake can be low Ovarian Cancer: High tumor-to-background contrast for peritoneal disease assessment Colorectal Cancer: Effective for staging and recurrence detection Head and Neck Cancers Esophageal Cancer Hepatocellular Carcinoma (HCC) Sarcomas: High FAP expression in many subtypes Thyroid Cancer Carcinoma of Unknown Primary: FAPI PET can detect the primary tumor site missed by FDG Who Needs a FAPI PET Scan? Your doctor may recommend a this PET/CT in Delhi in these clinical scenarios: FDG PET Scan was inconclusive or negative despite strong clinical suspicion of cancer Initial staging of cancers known to have high FAP expression (gastric, pancreatic, cholangiocarcinoma) Assessment of peritoneal carcinomatosis extent Radiotherapy treatment planning requiring precise tumor volume delineation Evaluation of cancer recurrence after treatment Carcinoma of unknown primary (CUP syndrome) Assessment of metastatic disease extent in complex anatomical regions (liver, brain) Evaluation for FAP-targeted radionuclide therapy eligibility Situations where inflammation confounds FDG PET interpretation Symptoms That May Lead to the procedure Unexplained abdominal pain or discomfort Unintentional significant weight loss Loss of appetite or early satiety Jaundice (yellow skin/eyes — suggestive of liver or bile duct pathology) Persistent cough or chest pain Abnormal tumour marker elevation (CA 19-9, CEA, AFP) Suspicious findings on CT or MRI requiring further characterization Fatigue and weakness not explained by other causes Palpable lymph node enlargement How the FAPI PET Scan Procedure Works The this scan works through a fundamentally different biological mechanism than FDG or PSMA PET. The Gallium-68 labelled

Prostate cancer is the second most common cancer in men worldwide, and in India it represents a growing health challenge. If you or someone you love has been diagnosed with prostate cancer — or if PSA levels are rising after treatment — your urologist or oncologist may recommend a PSMA PET Scan. Available at Neurad Diagnostics in Delhi, the 68Ga-PSMA PET/CT scan is the most advanced and accurate imaging technology for prostate cancer detection, staging, and monitoring available today. This comprehensive guide explains everything you need to know about this scan and why Neurad Diagnostics is the best choice in Delhi NCR. PSMA PET Scan at Neurad Diagnostics Delhi — Advanced prostate cancer molecular imaging Table of Contents What Is a the PSMA scan? Why Doctors Recommend the the procedure Diseases and Conditions Diagnosed by the PSMA scan Who Needs a this PET/CT? Symptoms That May Lead to PSMA PET Scan How the this imaging test Procedure Works Preparation Before the the PSMA scan Step-by-Step PSMA PET Scan Procedure at Neurad Diagnostics Advantages of Gallium-68 PSMA Technology Accuracy and Clinical Benefits of the procedure Safety Information Cost of PSMA PET Scan in Delhi NCR Choosing the Right Center for this scan in Delhi Why Choose Neurad Diagnostics for PSMA PET Scan in Delhi? Frequently Asked Questions About the PSMA scan 1. What does PSMA stand for? 2. At what PSA level should I get a PSMA PET Scan? 3. Is this scan better than bone scan for prostate cancer? 4. Can this imaging test be used for other cancers? 5. Does PSMA PET replace biopsy? 6. How is 68Ga-PSMA different from F-18 PSMA? 7. Will I be radioactive after the PSMA PET Scan? 8. How quickly can I get this PET/CT results? 9. Is PSMA PET Scan covered by insurance in India? 10. Where is the best this imaging test center in Delhi NCR? Conclusion — Book Your the PSMA scan at Neurad Diagnostics Delhi Today What Is a the PSMA scan? The this PET/CT, formally known as 68Ga-PSMA-11 PET/CT (or PSMA PET/CT), is a revolutionary nuclear medicine imaging study that uses a Gallium-68 labelled tracer targeting Prostate-Specific Membrane Antigen (PSMA) — a protein highly expressed on the surface of prostate cancer cells. When the tracer is injected into the bloodstream, it binds selectively to PSMA on prostate cancer cells throughout the body. The PET scanner detects the radioactive signal and creates detailed whole-body images showing exactly where prostate cancer cells are present — including primary tumor, lymph node involvement, bone metastases, and distant organ spread. PSMA PET Scan represents a quantum leap in prostate cancer imaging. It was approved by the US FDA in 2020-2021 and has rapidly become the global standard for prostate cancer staging and restaging. The European Association of Nuclear Medicine (EANM), the American Urological Association (AUA), and leading oncology bodies worldwide now recommend PSMA PET/CT as first-line imaging for high-risk and recurrent prostate cancer. Why Doctors Recommend the the procedure Urologists, oncologists, and radiation oncologists recommend the this scan because it provides information that conventional imaging simply cannot match. Traditional CT scans and bone scans miss the majority of prostate cancer metastases, particularly at low PSA levels — leading to under-staging, incorrect treatment selection, and missed opportunities for curative intervention. The PSMA PET Scan solves this problem by detecting disease at the molecular level, revealing metastases that are invisible on other scans. The clinical impact is profound: studies show that this imaging test changes treatment management in 50-70% of patients compared to conventional imaging. It allows surgeons to target the right lymph nodes, enables radiation oncologists to treat all sites of disease, and identifies patients suitable for the revolutionary Lu-177 PSMA therapy — a form of targeted nuclear medicine treatment for metastatic castration-resistant prostate cancer. Diseases and Conditions Diagnosed by the PSMA scan The PSMA PET Scan is used across multiple stages of prostate cancer management: Primary staging: Assessment of newly diagnosed high-risk or intermediate-risk prostate cancer before surgery or radiation Biochemical recurrence: Detection of disease recurrence when PSA rises after radical prostatectomy or radiotherapy Metastatic prostate cancer: Mapping the full extent of disease spread to lymph nodes, bones, and organs Treatment response monitoring: Evaluating response to androgen deprivation therapy, chemotherapy, or targeted treatments PSMA-targeted therapy selection: Confirming eligibility for Lu-177 PSMA-617 (Pluvicto) treatment Oligometastatic disease: Identifying limited metastases suitable for curative local treatment (metastasis-directed therapy) Who Needs a this PET/CT? Your doctor may recommend a the procedure in Delhi if you are in one of these situations: Newly diagnosed prostate cancer with high-risk features (PSA > 20, Gleason 8-10, or T3/T4 disease) Rising PSA after radical prostatectomy (even as low as 0.2 ng/mL) PSA rising after radiation therapy Known metastatic prostate cancer being re-staged Considering PSMA-targeted therapy (Lu-177 PSMA) Inconclusive findings on CT or bone scan Planning salvage lymph node dissection or salvage radiotherapy Monitoring response to systemic therapy Symptoms That May Lead to PSMA PET Scan While this scan is often ordered based on PSA levels or pathological findings rather than symptoms alone, the following clinical presentations may prompt your doctor to consider this investigation: Difficulty urinating or weak urine stream Frequent urination, especially at night Blood in urine or semen Pelvic pain or discomfort Bone pain (back, hip, or thigh) — suggestive of bone metastases Unexplained weight loss Elevated PSA detected on routine blood test Abnormal digital rectal examination findings Erectile dysfunction with other concerning features How the this imaging test Procedure Works The PSMA PET Scan works through molecular targeting. Gallium-68 is chelated to the PSMA-11 (or PSMA-617) ligand — a molecule specifically designed to bind to PSMA protein overexpressed on prostate cancer cells. After intravenous injection, the radiolabelled PSMA ligand circulates through the bloodstream and binds with high affinity to PSMA-expressing cells throughout the body. Normal tissues show minimal PSMA expression (and hence minimal tracer uptake), while prostate cancer cells light up brightly on the PET images. The PET/CT scanner integrates the functional PET signal (showing cancer cell location

If you or a loved one has been diagnosed with — or is suspected of having — a neuroendocrine tumor (NET), your oncologist or endocrinologist may recommend a DOTANOC PET Scan. Available at Neurad Diagnostics in Delhi, this advanced Gallium-68 this scan is one of the most precise imaging tools for detecting, staging, and monitoring neuroendocrine tumors anywhere in the body. In this comprehensive guide, we explain everything you need to know about the DOTANOC PET Scan — what it is, how it works, who needs it, and why Neurad Diagnostics is the best choice for this test in Delhi NCR. DOTANOC PET Scan at Neurad Diagnostics, Delhi — The gold standard for neuroendocrine tumor detection Table of Contents What Is a this scan? Why Doctors Recommend the DOTANOC PET Scan Diseases Diagnosed by this imaging study Who Needs This Test? Symptoms That May Require This Scan How the Procedure Works Preparation Before the the test Step-by-Step DOTANOC PET Scan Procedure at Neurad Diagnostics Advantages of Gallium-68 DOTANOC Technology Accuracy and Clinical Benefits Safety Information Cost Factors for this PET/CT in Delhi NCR Choosing the Right Diagnostic Center for the procedure in Delhi Why Choose Neurad Diagnostics for DOTANOC PET Scan in Delhi? Frequently Asked Questions About this scan 1. What is a this imaging study? 2. How is DOTANOC different from FDG PET Scan? 3. How long does the DOTANOC PET Scan take? 4. Is the the test painful? 5. Do I need to stop my octreotide before the DOTANOC scan? 6. What is the radiation dose from this PET/CT? 7. Can DOTANOC PET Scan detect metastatic NETs? 8. Is the procedure used before PRRT treatment? 9. Where can I get this scan in Delhi NCR? 10. How soon will I get my DOTANOC PET Scan report? Conclusion — Book Your this imaging study at Neurad Diagnostics Today What Is a the test? The DOTANOC PET Scan, formally known as the 68Ga-DOTANOC PET/CT scan, is a type of nuclear medicine imaging study that uses a radioactive tracer called Gallium-68 DOTANOC. This tracer is a somatostatin analogue — meaning it binds specifically to somatostatin receptors (SSTR2, SSTR3, and SSTR5) that are overexpressed on the surface of neuroendocrine tumor cells. When injected into the patient’s bloodstream, the Gallium-68 tracer accumulates in areas of the body where NETs are present and emits positron radiation that is detected by the PET/CT scanner, producing highly detailed three-dimensional images of tumor location, size, and spread. Unlike conventional FDG-PET scans used for most cancers, the this PET/CT is specifically engineered for neuroendocrine tumors, which often go undetected on standard imaging. It is considered the gold standard diagnostic tool for NETs worldwide and is endorsed by leading nuclear medicine bodies including the European Association of Nuclear Medicine (EANM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI). Why Doctors Recommend the the procedure Oncologists, endocrinologists, and gastroenterologists recommend the DOTANOC PET Scan for a range of critical clinical reasons. First, it provides whole-body staging of neuroendocrine tumors in a single session, something that multiple CT, MRI, or ultrasound studies cannot achieve. Second, it helps determine whether a patient is eligible for Peptide Receptor Radionuclide Therapy (PRRT) — a targeted nuclear medicine treatment for NETs — by confirming adequate somatostatin receptor expression. Third, it is used to monitor how well treatment is working and to detect recurrence early. Doctors across India rely on this scan for its superior sensitivity and specificity, which surpasses conventional imaging. Clinical studies have repeatedly shown detection rates exceeding 90% for well-differentiated NETs — far better than CT or MRI alone. In the Indian context, where many patients present late, this test provides a critical advantage in catching tumors before they spread further. Diseases Diagnosed by this imaging study The DOTANOC PET Scan is primarily used to diagnose and evaluate a broad range of somatostatin receptor-positive tumors. These include: Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) — tumors of the stomach, small intestine, colon, rectum, and pancreas Pancreatic NETs (pNETs) — including insulinomas and gastrinomas Carcinoid Tumors — slow-growing NETs of the digestive tract and lungs Pheochromocytoma and Paraganglioma — adrenal and extra-adrenal chromaffin cell tumors Medullary Thyroid Carcinoma — thyroid cancer expressing somatostatin receptors Small Cell Lung Cancer — neuroendocrine tumors of the lung Merkel Cell Carcinoma — rare skin neuroendocrine tumor Neuroblastoma and Meningioma — especially for receptor scintigraphy Who Needs This Test? Your doctor may recommend a the test in Delhi if you fall into one or more of these categories: You have been diagnosed with a neuroendocrine tumor and need staging You have unexplained elevated chromogranin A, serotonin, or urinary 5-HIAA levels You experience symptoms suggestive of carcinoid syndrome (flushing, diarrhea, palpitations) You have a known NET and are being evaluated for PRRT treatment You are being followed up after NET surgery or treatment You have a pancreatic mass with features suggesting a functional or non-functional NET You have suspected pheochromocytoma or paraganglioma Your oncologist wants to rule out metastases from a primary NET Symptoms That May Require This Scan Neuroendocrine tumors often produce hormones that cause a distinct set of symptoms. If you experience any of the following, your physician may order a this PET/CT: Unexplained episodes of skin flushing (redness of face and neck) Chronic or intermittent diarrhea not explained by other causes Abdominal pain or bloating Unexplained weight loss Wheezing or breathlessness (carcinoid syndrome) High blood pressure episodes (pheochromocytoma) Low blood sugar (hypoglycemia from insulinoma) Peptic ulcers resistant to treatment (Zollinger-Ellison syndrome from gastrinoma) Fatigue and general weakness How the Procedure Works The 68Ga-DOTANOC PET/CT scan works through molecular imaging. Gallium-68 is a cyclotron-produced or generator-produced radioactive isotope with a half-life of approximately 68 minutes. It is chelated to the peptide DOTANOC (DOTA-1-Nal3-octreotide), which has a high affinity for somatostatin receptors subtype 2, 3, and 5. Once injected intravenously, this labelled compound travels through the bloodstream and preferentially accumulates in cells with high somatostatin receptor density — primarily NET cells — while being cleared from normal tissues within